💊 Hims & Hers: When the Growth Story Runs Into the Regulator

Summary

In this episode Edward Corona dissects the sudden 16% plunge of Hims & Hers Health (HIMS), linking it to a dual blow from GLP‑1 hype‑driven expectations and mounting legal and FDA scrutiny. He explains how lawsuits and regulatory pressure are directly challenging the company’s core growth narrative, forcing a reassessment of its business model. Corona highlights the broader market implications for other tele‑health and consumer‑health firms riding similar hype cycles, and offers tactical insights for traders navigating the fallout.